SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 228 filers reported holding SAGE THERAPEUTICS INC in Q3 2021. The put-call ratio across all filers is 2.20 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $3,000 | 0.0% | 81 | 0.0% | 0.00% | – |
| Q4 2021 | $3,000 | -25.0% | 81 | 0.0% | 0.00% | – |
| Q3 2021 | $4,000 | -20.0% | 81 | 0.0% | 0.00% | – |
| Q2 2021 | $5,000 | -16.7% | 81 | 0.0% | 0.00% | – |
| Q1 2021 | $6,000 | -85.0% | 81 | -80.5% | 0.00% | – |
| Q4 2018 | $40,000 | -25.9% | 416 | +8.9% | 0.00% | – |
| Q3 2018 | $54,000 | -61.7% | 382 | -83.1% | 0.00% | -100.0% |
| Q3 2017 | $141,000 | -91.6% | 2,263 | -93.1% | 0.00% | -87.5% |
| Q4 2016 | $1,673,000 | +10.5% | 32,764 | -0.3% | 0.01% | 0.0% |
| Q3 2016 | $1,514,000 | +53.1% | 32,865 | +0.1% | 0.01% | +60.0% |
| Q2 2016 | $989,000 | -8.8% | 32,828 | -3.0% | 0.01% | -16.7% |
| Q1 2016 | $1,085,000 | -43.3% | 33,849 | +3.1% | 0.01% | -45.5% |
| Q4 2015 | $1,914,000 | +37.7% | 32,830 | -0.0% | 0.01% | +37.5% |
| Q3 2015 | $1,390,000 | +34.8% | 32,831 | +132.4% | 0.01% | +60.0% |
| Q2 2015 | $1,031,000 | +51450.0% | 14,128 | +33538.1% | 0.01% | – |
| Q1 2015 | $2,000 | – | 42 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sio Capital Management, LLC | 179,200 | $29,516,000 | 16.65% |
| TRV GP II, LLC | 547,916 | $90,247,000 | 16.25% |
| Opus Point Partners Management, LLC | 71,000 | $11,694,000 | 10.12% |
| Casdin Capital, LLC | 250,000 | $41,178,000 | 10.03% |
| RA Capital Management | 455,173 | $74,972,000 | 6.27% |
| Crawford Lake Capital Management, LLC | 154,278 | $25,411,000 | 6.00% |
| Palo Alto Investors LP | 810,806 | $133,548,000 | 5.75% |
| GREAT POINT PARTNERS LLC | 200,000 | $32,942,000 | 5.62% |
| BB BIOTECH AG | 1,042,439 | $171,700,000 | 4.84% |
| Crawford Lake Capital Management, LLC | 92,300 | $15,203,000 | 3.59% |